Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net income shifted from a loss of US$43.2 million in Q4 2024 to a profit of US$59.0 million in Q4 2025 as margins turned positive.
See our full analysis for Kiniksa Pharmaceuticals International.
With the headline numbers on the table, the next step is to see how this shift in profitability lines up with the broader market and community narratives around Kiniksa, and where those stories might need updating.
See what the community is saying about Kiniksa Pharmaceuticals International
Five year earnings growth around 40%
- Over the last five years, earnings are reported as growing at about 40% a year, and the latest trailing twelve month net income sits at US$59.0 million on revenue of US$677.6 million.
- Consensus narrative sees this earnings profile as part of a longer growth story, with forecasts of roughly 23.3% annual revenue growth and margins rising from about 0.9% to 19.1%. However, the move from a trailing twelve month loss of US$43.2 million in Q4 2024 to a profit of US$59.0 million in Q4 2025 means that a lot of the improvement has already shown up in reported numbers.
- Supporters of the consensus view point to the trailing twelve month Basic EPS turning from a loss of US$0.60 in Q4 2024 to a profit of US$0.80 by Q4 2025 as evidence that profitability is already established rather than purely theoretical.
- At the same time, those same forecasts assume earnings reaching US$189.0 million by around 2028, which is materially higher than the current US$59.0 million base, so anyone relying on that path still needs to think about execution risk around that gap.
P/E of 55.5x and DCF fair value tension
- The trailing P/E of 55.5x sits above both the US Biotechs industry average of 22.1x and a peer average of 14.1x, while a DCF fair value of US$148.61 is well above the current share price of US$42.76.
- Bulls argue that the combination of about 31.1% forecast annual earnings growth and a DCF fair value of US$148.61 more than justifies paying a higher multiple today. Yet the current P/E of 55.5x compared with an implied future P/E of 24.2x in the consensus narrative shows that a lot of multiple compression is already baked into those optimistic scenarios.
- On the bullish side, the data flags that the share price is around 71.2% below the DCF fair value, which supports the idea of upside if those growth assumptions play out.
- On the other hand, the same dataset highlights that the stock already trades at more than double the industry P/E, so anyone leaning on the bullish case needs to be comfortable that earnings growth of around 31.1% a year is enough to grow into that starting multiple.
High growth forecasts versus single product risk
- Forecasts in the data point to about 14.6% annual revenue growth and roughly 31.1% annual earnings growth over the next few years, while the company currently relies heavily on ARCALYST as the main driver behind the US$677.6 million of trailing twelve month revenue.
- Bears focus on that reliance on one flagship therapy, arguing that even with earnings expected to reach US$135.1 million in a more cautious case, competition, payer pressure, and R&D spend for pipeline assets could limit how much of the projected 21.0% to 23.3% revenue growth actually flows through to sustained profits.
- Cautious investors point out that both bullish and bearish scenarios still assume higher future P/E ratios than the current US Biotechs average of about 15%, which leaves less room for error if ARCALYST growth slows or pipeline assets such as KPL 387 do not meet expectations.
- At the same time, the shift from a trailing twelve month loss of US$43.2 million to a profit of US$59.0 million shows that current profitability depends heavily on one product, so any change in pricing or reimbursement could have an outsized effect on those growth paths.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Kiniksa Pharmaceuticals International on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
With all that in mind, do these numbers make you optimistic or cautious about where Kiniksa stands today? If you want to move quickly and build your own view from the core figures, it is worth checking the 4 key rewards that are currently catching investors’ attention.
Explore Alternatives
Kiniksa’s high P/E of 55.5x relative to biotech peers, combined with reliance on a single product, leaves little margin for error if expectations shift.
If that kind of pricing and concentration risk makes you uneasy, it is worth checking a list of 80 resilient stocks with low risk scores that screen for more resilient profiles right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com